Photo

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Photo

Devastated by tornado

A huge tornado tears through the Oklahoma City suburb of Moore, killing dozens.  Slideshow 

Photo

Nuclear tsunami wall

Safety upgrades designed to prevent a repeat of the Fukushima disaster.  Slideshow 

Sponsored Links

Russian billionaire invests in U.S. genetics company 23andMe

Digital Sky Technologies CEO Yuri Milner attends the eG8 forum in Paris May 25, 2011. REUTERS/Gonzalo Fuentes

Digital Sky Technologies CEO Yuri Milner attends the eG8 forum in Paris May 25, 2011.

Credit: Reuters/Gonzalo Fuentes

SAN FRANCISCO | Tue Dec 11, 2012 7:20pm EST

SAN FRANCISCO (Reuters) - Russian billionaire Yuri Milner, best-known for investments linking consumers to the Internet, is placing a bet on genetics.

Milner, who backed companies ranging from Facebook Inc to gaming company Zynga Inc, has led a $50 million funding round into 23andMe, a Mountain View, California, company that helps people decipher their genetic makeup.

His investment could shine a spotlight on biotechnology startups, which have taken a backseat in visibility to sectors like cloud computing and Internet services targeted at consumers.

23andMe, named for the 23 pairs of chromosomes that make up each person's genome, also announced a price drop for its saliva-based test, to $99 from $299.

For that price, consumers learn specifics about ancestry and genetic traits, including the possible conditions and diseases to which they may have a genetic propensity.

Existing investors joining the funding round include Anne Wojcicki, 23andMe's chief executive; Sergey Brin, Wojcicki's husband and co-founder of Google Inc; New Enterprise Associates; Google Ventures; and MPM Capital.

The company's last funding round was about $31 million, raised two years ago. Since its founding in 2006, 23andMe has raised about $68 million.

Biotechnology has fostered some hefty investment exits recently. On Monday, Amgen Inc said it would pay $415 million for Iceland-based Decode Genetics.

(Editing by Matthew Lewis)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.